Skip to main content
Fig. 1 | Experimental Hematology & Oncology

Fig. 1

From: Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia

Fig. 1

a Kaplan–Meier curve for the first onset of liver dysfunction (> grade 1). The median time of the first appearance of liver dysfunction was 57 days in patients receiving the standard dose regimen; however, that was not reached in patients on dose escalation regimen (P = 0.029, log-rank test). b Comparison of plasma trough concentration of bosutinib in patients with liver dysfunction (> grade 1, n = 9), as well as those without (n = 16). There was no statistically significant difference in the plasma trough concentration between the two groups (P = 0.066, Mann–Whitney U test). c Kaplan–Meier curve for the first onset of diarrhea. The median time of the first appearance of diarrhea was 1 day in patients receiving the standard dose regimen and 29 days in patients receiving the dose escalation regimen (P < 0.001, log-rank test). d Comparison of plasma trough concentration of bosutinib in patients with delayed/prolonged diarrhea, which occurred after day 14 (n = 11), as well as those without symptoms (n = 14). There was a statistically significant difference in plasma trough concentration between these two groups (P = 0.007, Mann–Whitney U test)

Back to article page